Hims & Hers back in red as FDA doubles down on GLP-1 compounders

Following over a 13% gain in the prior session, Hims & Hers (HIMS) traded lower after the U.S. FDA sent a new batch of warning letters to telehealth firms that illegally market low-cost compounded versions of GLP-1s, the popular class of

Leave a Reply

Your email address will not be published. Required fields are marked *